bioAffinity Technologies News Update
SAN ANTONIO, Texas (July 3, 2024) – We are pleased to share the latest updates from bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) as we continue to accelerate the commercialization of CyPath® Lung, our noninvasive diagnostic test to aid in the early detection of lung cancer.
CEO Maria Zannes Interview on Bloomberg TV
bioAffinity Technologies CEO Maria Zannes will be featured on RedChip’s Small Stocks Big Money™ show, a sponsored program on Bloomberg TV. The interview will air on Saturday, July 6, 2024, at 7 p.m. ET. Bloomberg TV is available in an estimated 73 million homes across the U.S., providing a substantial platform to discuss bioAffinity’s innovative contributions to lung health and cancer diagnostics. View the interview here.
Accelerating Growth in CyPath® Lung Adoption
We continue to see a significant increase in the number of physicians and pulmonology practices adopting CyPath® Lung. On June 10, we reported 139% growth in the number of practices offering CyPath® Lung since January 1, 2024. This expansion has extended beyond Texas to include eight additional states: New Jersey, Ohio, Pennsylvania, Michigan, North Carolina, California, Florida, and Arizona. This rapid adoption is driven by positive word-of-mouth among physicians, highlighting CyPath® Lung’s high sensitivity and specificity and its ability to meet the unmet need for early detection of lung cancer.
Video Testimonial from Dr. Daya Nadarajah
Dr. Daya Nadarajah, a renowned pulmonologist from Newton, New Jersey, celebrated a significant milestone when he recently administered his 50th CyPath® Lung test. Dr. Nadarajah has been in practice for more than 20 years and is affiliated with multiple hospitals, including Hackettstown Medical Center and Newton Medical Center. You can view a compelling video testimonial from Dr. Nadarajah on the benefits of CyPath® Lung here.
For more information, visit bioaffinitytech.com and follow us on LinkedIn, Facebook, and X (Twitter). We wish you a HAPPY JULY 4th holiday. Thank you for your continued support.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company continuing to accelerate the commercialization of CyPath® Lung, discussing bioAffinity’s contributions to lung health and cancer diagnostics on RedChip’s Small Stocks Big Money™ show and the ability of CyPath® Lung to meet the unmet need for early detection of lung cancer. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to accelerate the commercialization of CyPath® Lung and capitalize on the lung cancer diagnostics market; the ability of CyPath® Lung to provide the anticipated benefits to patients and physicians; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Contacts
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
BIAF@redchip.com
